Study ID: [REMOVED]
This NCT number has been applied to the document for 
purposes of posting on Clinicaltrials.gov

Statistical Analysis Plan: 15-A VP-786-202 
1 TABLE OF CONTENTS 
1 TABLE OF CONTENTS .................................................................. .......... ........... ............ 2 
LIST OF TABLES ............ ......................... ........ .................. .. ....... ....................... ...................... 5 
LIST OF FIGURES ... .................... ............ .......................................... ............................. ......... 5 
LIST OF APPENDICES ............... .. ....................................................... .................. .................. 5 
2 SIGNATURE PAGE ........................... .... ..................... .. .. .. ................. ................. ............. 6 
3 LIST OF ABBREVI ATIONS AND DEFINITIONS OF TERMS ............... .......... ........ ... 7 
4 INTRODUCTION ................................................ ...................... .... ................................. .. 9 
5 TRIAL OBJECTIVES ........... ............. ................................. .................... .......................... 9 
5.1 Primary Objectives ............................................................... .................. .................. 9 
5.2 Secondary Objectives ........... ............. ................................................................... .... 9 
6 STUDY DESI GN CONSIDERATIONS .. .......... .......... .. .. .. .. ............................ ................. 9 
6.1 Stud y Design and Popul ation .............. .. ............ ........ ........ .................................... ... 9 
6.2 Stud y Drug Administration .................. .. ................................ ............................ .. .. 11 
........ ......... ..... ..... ....................... ................................................. 12 
7 STUDY ENDPOINTS ....... ............................................................. ........... .. .................... 12 
7 .1 Scales and Questio1maires ................................... ................. ............................ ... ... 12 
7.1.l 16-Item and 4-Item Negative Symptom Assessments (NSA- 16, NSA-4) .. .12 
7.1.2 Positi ve and Negative Syndrome Scale (PANSS) ........ .. ............ .. ............... 13 
7.1.3 Clinical Global Impression (CGI) Scales .......... ............. .............. .. ............. 14 
7.1.3.l Clinical Global Impression-Se verity (CGI-S) .. .............. ................ .15 
7.1.3.2 Clinical Global Impression :--Change (CGI -C) ............................ ..... 15 
7 .1.3 .3 Patient Global Impression -Change (PGIC) ...... ...... .............. .......... .15 
7 .1.4 Calgary Depression Scale for Schizophrenia (CDSS) ...................... ........... 16 
7.1.5 Measurement and Treatment Resea rch to Improve Cognition in 
Schizophreni a (MA TRI CS) Consensus Cognitive Battery (MCCB) .......... 16 
7 .1. 6 Effort Expenditure for Reward Task (EEfR T) .. ........... ................ .......... ...... 16 
................... .......... ........ .. .. .............. ... 17 
7.1.8 Mini International Neuropsychiatric Interview (M.I.N.I.) Version 6.0.0 .... 17 
7.1.9 Columbia Suicide Severity Rating Scale (C-SSRS) .............................. .. .... 17 
7.1.10 Simpso n Angus Scale for Extrapyramidal Symptoms (SAS) ... .. .. .. ............. 18 
7 .1.11 Barnes Akathisia Scale (BAS) .............. .................... .......... ..... .... ................ 18 
7.1.12 Abnormal Involuntar y Movements Scale (AIMS) ............ .. .. .. ........ .......... .. 18 
7 .2 Efficac y Endpoints .............. ........ ...................... ............ ....................... .. ................ 18 
7 .3 Safety Endpo ints ............... ......................... .. .............. ...................... .................. .... 19 
7.4 Pharmacokinetic ,  Parameters .. ........................... .. ........ 19 
8 ANALYSIS POPULA TIONS ...................... .. ................ ............ ....................... ........... ... 19 
8.1 Modified Intent -to-Treat (mITT) Population ....... .. .................. .. ........ .. .. .. .... .......... 20 
...... .. .. .. ........ .................. .. .................... .............. .... 20 
Confidential Page 2 of52 

Statistical Analysis Plan: 15-A VP-786-202 
................... ........... ......... .. .............................. 20 
. .... ................................ ................ ................. . 21 
8.3 Safety Population ...... ........................................ ..................................................... 21 
... .................... ............ 21 
................................... 21 
.......... .............. .......... . 21 
....... ............. ............... 21 
9 OVERALL STATISTICAL CONSIDERATIONS .............. .................. .. .. ..................... 22 
9 .1 Definition of Baseline ............. .......... .............................................. ............ ........... 22 
9.2 Definition of End ofTreatment.. ........................... ............ ........ .. .. .. ............... .... .. .. 22 
9.3 Change from Baseline .................. ........ ................. ................. ............................ .... 22 
9.4 Visit Windows ............................................................... .......... ................. ............. 22 
9.5 Handling of Missing Data .............. ........................................................................ 24 
9.6 Treatment Misallocations ....... .. .............. ............. ................................................... 24 
9.7 Summary Statistics .......... ..................................... ......... ......................................... 25 
9.8 Data Listings ........................ ....................................... ......................................... .. 25 
9.9 Graphical Displays .......... .................................. .................... ................... .............. 25 
9 .10 Hypothesis Testing .......................................... .................. .................................. ... 25 
9 .11 Multiplicity of Secondary Endpoints .......................... .................... ....................... 25 
10 EFFICACY STATISTICAL ANALYSIS METHODS ............................. ...................... 25 
10.1 Primary Efficacy: SPCD MMRM (Mixed-Model Repeated Measures) ............... 25 
........ 26 
........ 26 
........ 27 
........ 28 
10.3 Secondary Efficacy Analysis ................ ........................... .................................... .. 28 
10.3.1 Secondary SPCD MMRM and SPCD OLS ANCOVA ......................... ...... 29 
10.3.2 P ANSS Response Analysis ....... ........................... ................. ..................... .. 29 
.... .. .29 
...... 30 
...... 30 
...... 30 
...... 30 
...... 30 
...... 31 
...... 31 
...... 31 
Confidential Page 3 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
.. 32 
... 32 
11 SAFETY STATISTICAL ANALYSIS METHODS ........................... .................. .......... 33 
11.1 Adverse Events .......... ..... ................. ..................... ........ ................ .... ..................... 34 
11.2 Clinical Laboratory Assessments ........................ ........................................... ........ 36 
11.3 ECGs ................................................................ ......... ......... ....... ............................. 37 
11.4 Vital Signs ............... ........................ ........................................ ....................... ...... .. 38 
11.5 Physical and Neurological Exams .............. ................................. .......................... 39 
11.6 C-SSRS .......................... ................. ........................................... ....................... ..... 39 
11. 7 Simpson Angus Scale for Extrapyramidal Symptoms (SAS) ................. .. ............ .40 
11.8 Barnes Akathisia Scale (BAS) ................................................................. ............. .40 
11.9 Abnonnal Involuntary Movement Scale (AIMS) .................... .. ........... ............... . .40 
12 ADDITIONAL STATISTICAL ANALYSIS METHODS ...................... ...................... .41 
12.1 Patient Disposition .......................................................... ...................... ................ .41 
12.2 Demographics and Baseline Characteristics .................................................... ..... .41 
12.3 Medical History and Disease Characteristics ....... .. .... .. ................................ .... ..... 42 
12.4 Exposure and Treatment Compliance .................... .. ........... .................................. .42 
12.5 Prior and Concomitant Medications ................... .................. ................................ .43 
12.6 Analysis of Phaimacokinetics and Pharmacod ynamics ....................... ................. .43 
13 ADDITIONAL STATISTICAL CONSIDERATIONS ........... ............................... ......... 44 
13.1 Data Safet y Monitoring Board (DSMB) ........ ....... ................. ........................... .. .. .44 
13.2 Change s from Protocol ........... ..... ...................................... ................................... .44 
14 REFERENCES ....................... ..................... .......................... .......................................... 45 
15 APPENDICES ........... ......... ............ ........... .................. ....................................... ............. 46 
Confidential Page 4 of52 

Statistical Analysis Plan: 15-A VP-786-202 
LIST OF TABLES 
Table 1. Overview of Study Durati on ...... ....................... ...................... ........ .......... .. ................. 9 
Table 2. Visit Windows for Assessment s Done at Baseline and Weeks 2, 3, 6, 8, 9, 12 ........ 23 
Table 3. Visit Windows for Assessments Done at Baseline and Weeks 3, 6, 9, and 12 ........ .23 
Table 4. Visit Windows for Assessments Done at Baseline, Week 6, and Week 12 Only ..... 23 
Table 5. Lab PCS Criteria ............... ....... .......................... ....................... ................. ............ .... 37 
Table 6. ECG PCS Criteria ...................... ......... .......... ............................................................. 38 
Table 7. Vital Sign PCS Criteria ....... .. ......... ....................... ......................... ............................ 39 
LIST OF FIGURES 
Figure 1. Study Schematic (With Treatment Segments) ............... .................... .................... .11 
LIST OF APPENDICES 
Appendix 1 Schedule of Assessments and Procedures .................................. ......................... .47 
.. .............. ............. .. .................... .48 
Appendix 3 Prior and Concomitant Medication Start Date Imputation .............. .................... 50 
 ....... 51 
Appendix 5 List of Selective serotonin -norepinepherine reuptake inhibitors (SNRis) ........... 52 
Confidential Page 5 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
2 SIGNATURE PAGE 
Study Title: A Phase 2, Multicenter, Randomized , Double-Blind, Placebo-
Controlled Study to Assess the Efficacy , Safety, and Tolerability 
of A VP-786 (Deuterium Modified Dextromethorphan 
Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in 
Patients with Residual Schizophrenia 
Study Number: 15-A VP-786-202 
Prepared by: 
Approved by
Approved by
Approved by
Approved by:
Approved by:
Confidential Page 6 of 52 8/15/2017 
8/15/2017 
8/15/2017 
8/15/2017 
8/15/2017 
8/15/2017 

Statistical Analysis Plan: 15-A VP-786-202 
3 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
AA 
AE 
AIMS 
ALT/SGPT 
ANCOVA 
AST/SGOT 
AUC 
AVP-786 
BAS 
BID 
BP 
bpm 
BUN 
Cm ax 
CDSS 
CFBL 
CGI-C 
CGI-S 
CK 
C-SSRS 
 
d6-DM 
DM 
DSMB 
DSM-IV-TR 
ECG 
eCRF 
EEtRT 
FDA 
GGT 
HbAlc 
HR 
ICF 
ITT 
LDH 
LOCF 
Confidential Apathy avolition 
Adverse event 
Abnormal Involuntary Movements Scale 
Alanine aminotransferase/serum glutamic-pyruvic transaminase 
Analysis of covariance 
Aspartate aminotransferase/serum glutamic-oxaloacetic transaminase 
Area under the concentration-time curve 
Deuterated [ d6]-dextromethorphan hydro bromide and quinidine sulfate 
combination 
Barnes Akathisia Scale 
Twice-daily 
Blood pressure 
Beats per minute 
Blood urea nitrogen 
Maximum plasma concentration 
Calgary Depression Scale for Schizophrenia 
Change from Baseline 
Clinical Global Impression of Change 
Clinical Global Impression of Severity of Illness 
Creatine kinase 
Columbia Suicide Severity Rating Scale 
 Subject Database 
Deuterated ( d6)-dextromethorphan hydro bromide 
Dextromethorphan hydrobromide 
Data and Safety Monitoring Board 
Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text 
Revision 
Electrocardiogram 
Electronic case report form 
Effort Expenditure for Reward Task 
US Food and Drug Administration 
Gamma-gl utamyl transferase 
Glycosylated hemoglobin 
Heart rate 
Informed Consent Form 
Intent-to-Treat 
Lactate dehydrogenase 
Last observation carried forward 
Page 7 of 52 

Statistical Analysis Plan : 15-A VP-786-202 
M.l.N.I. 
MATRICS 
MCCB 
MedDRA 
mg 
mITT 
MMRM 
NSA-16 
NSA-4 
OLS 
PANSS 
PCS 
PD 
PGIC 
pH 
PK 
pp 
PT 
Q 
QD 
QRS 
QT 
QTc 
QTcF 
SAE 
SAP 
SAS 
SAS® 
SGA 
soc 
SNRI 
SPCD 
SSRI 
SUR 
TEAE 
TFLs 
ULN 
us 
WHO 
Confidential Mini International Neuropsychiatric Interview 
Measurement and Treatment Research to Improve Cognition in 
Schizophrenia 
MATRICS Consensus Cognitive Battery 
Medical Dictionary for Regulatory Activities 
Milligram( s) 
Modified Intent-to-Treat 
Mixed-effects model for repeated measures 
16-Item Negative Symptom Assessment 
4-Item Negative Symptom Assessment 
Ordinary least squares 
Positive and Negative Syndrome Scale 
Potentially clinically significant 
Pharmacod ynamic( s) 
Patient Global Impression of Change 
Potential hydrogen 
Pharmacokinetic( s) 
Per-protocol 
Preferred Term 
Quinidine (sulfate) 
Once daily 
The Q-R-S complex from an ECG tracing 
QT interval from an ECG tracing 
QT interval corrected for heart rate 
QT interval corrected for heart rate using the Fridericia's fo1mula 
Serious adverse event 
Statistical analysis plan 
Simpson Angus Scale for Extrapyramidal Symptoms 
Statistical Analysis Software 
Second generation antipsychotic 
System Organ Class 
Selective serotonin-norepinephrine reuptake inhibitor 
Sequential parallel comparison design 
Selective serotonin reuptake inhibitor 
Seemingly unrelated regression 
Treatment-emergent adverse event 
Tables, figures, and listings 
Upper limit of normal 
United States of America 
World Health Organization 
Page 8 of 52 

Statistical Analysis Plan: 15-AVP-786-202 
4 INTRODUCTION 
This document provides a detailed description of the statistical methods and procedures to be 
implemented during the analysis of Avanir Pharmaceuticals Incorporated Protocol 15-AVP-
786-202 (Amendment 4, Version 5), dated 25 January 2016. 
5 TRIAL OBJECTIVES 
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of 
A VP-786, a combination of deuterated-dextromethorphan hydro bromide ( d6-DM) and 
quinidine sulfate (Q), as an adjunctive therapy compared with placebo in patients with 
residual schizophrenia on negative and positive symptoms and cognitive function. 
5.1 Primary Objectives 
The primary study objective is to evaluate the efficacy of A VP-786 compared to placebo for 
the treatment of negative symptoms associated with schizophrenia, as measured by the 16-
item Negative Symptom Assessment (NSA-16) total score. 
5.2 Secondary Objectives 
The secondary objectives of this study are to evaluate the efficacy, safety, and tolerability of 
A VP-786 compared to placebo in patients with residual schizophrenia. 
• Clinical Efficacy will be measured by the Positive and Negative Syndrome Scale 
(PANSS) total score and PANSS subscales; NSA-16 factor domains, global score, 
individual items, and NSA-4; proportion of patients with a reduction of20% or 
greater in the PANSS total score; MCCB composite score, CGI-S, CGI-C, and PGIC 
scores; CDSS; and EEfRT. 
• Safety and tolerability will be measured by reported AEs, SAEs, physical 
examinations, vital signs, weight, pregnancy tests, clinical laboratory assessments, 
12-lead ECGs, as well as C-SSRS, AIMS, BAS, and SAS scales. 
6 STUDY DESIGN CONSIDERATIONS 
6.1 Study Design and Population 
This is a prospective, multicenter, randomized, double-blind, placebo-controlled study with a 
duration of 12 weeks, consisting of 2 consecutive double-blind treatment stages, each 6 
weeks in duration (Stage 1 and Stage 2). The study utilizes a Sequential Parallel Comparison 
Design (SPCD). 
Table 1. Overview of Study Duration 
Screening Stage I Stage 2 Telephone Follow-Up 
Duration in Days Day-28 to -7 Day 1to42 Day 43 to 85 Day 86 to 90 
Confidential Page 9 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
Approximately 120 patients will participate in the study at roughly 15 research centers in the 
United States . Eligible patients for this study must be adult outpatients (between 18 and 60 
years of age) who are diagnosed with schizophrenia, are clinically stable, in a residual (non-
acute) phase of illness, and will have been treated with a second generation antipsychotic 
(SGA) agent for at least 3 months (90 days) and on a stable dose for 1 month (30 days) prior 
to the Screening Visit. The diagnosis of residual schizophrenia will be based on the 
Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-
TR). 
Initial randomization will occur at baseline and will mark the start of Stage 1. Patients will 
be randomized in a  ratio (A VP-786 to placebo). 
Patients who have completed Stage 1 are eligible to participate in Stage 2 of the study , which 
is also 6 weeks long. Stage 2 starts at Week 7 and will continue to the end of Week 12. 
Patients who received placebo in Stage 1 will be further stratified into 2 subgroups 
("responders" and "non-responders ") based on their response to the  
 from the Baseline total score 
constitutes a response. Each subgroup will be re-randomized to receive A VP-786 or placebo 
in a  ratio. Patients who received A VP-786 in Stage 1 will continue to receive A VP-786 
for the entire 6-week duration of Stage 2. 
Clinic visits will occur at Screening, BaselineNisit 1 (Day 1 ), Week 2Nisit 2 (Day 15), 
Week 3Nisit 3 (Day 22), Week 6Nisit 4 (Day 43), Week 8Nisit 5 (Day 57), Week 9Nisit 6 
(Day 64), and Week 12/Visit 7/Early Termination (Day 85). A schematic of the study along 
with the visit schedule and treatment segments is shown in Figure 1. The letters for each 
treatment segment are described below and will be used throughout the Statistical Analysis 
Plan (SAP) for clarity: 
• A: A= Al + A2, where Al and A2 are the Stage 1 data for patients who are 
randomized to Placebo/Placebo and Placebo/AVP-786, respectively. 
• B: Stage 1 data for patients randomized to A VP-786 in Stage 1 
• C: Stage 2 data for patients who were placebo 'responders' in Stage 1 and 
re-randomized to placebo in Stage 2 
• D: Stage 2 data for patients who were placebo 'responders ' in Stage 1 and 
re-randomized to A VP-786 in Stage 2 
• E: Stage 2 data for patients who were placebo 'non-responders' in Stage 1 and 
re-randomized to placebo in Stage 2 
• F: Stage 2 data for patients who were placebo 'non-responders ' in Stage 1 and 
re-randomized to AVP-786 in Stage 2 
• G: Stage 2 A VP-786 data for patients randomized to A VP-786 in Stage 1. 
Confidential Page 10 of 52 

Statistical Analysis Plan : 15-A VP-786-202 
Figure 1. Study Schematic (With Treatment Segments) 
Protocol 15-AVP-786-202 (Schizophrenia Study) 
Stratification by Site Stratification based on Treatment Response 
Randomization Baseline/Visit 1(Day1) Re-Randomization Visit 4 (Day 43)' 
Placebo c 
~-""l D .......... 
AVP-786 
M 34/4 .9 34/4 .9 34/4 .9 34/4 .9 
E Placebo 34/4 .9 34/4 .9 34/4.9 34/4 .9 Placebo A(= Al+A2)** 
Placebo E 
,00~'"'"""1 F 
Screening AVP-786 
M 34/4.9 34/4 .9 34/4 .9 34/4 .9 
E Placebo 34/4.9 34/4 .9 34/4.9 34/4.9 
B G 
AVP-786 AVP-786 
M 34/4.9 34/4.9 34/4 .9 34/4 .9 M 34/4.9 34/4 .9 34/4 .9 34/4 .9 34/4 .9 34/4 .9 
E Placebo 34/4 .9 34/4.9 34/4 .9 34/4 .9 E 34/4.9 34/4 .9 34/4 .9 34/4 .9 34/4.9 34/4 .9 
Period Screening Stage 1 Stage 2 
Visit Screening Baseline I I V3 I I I V4' I I V6 I I I V7 
Day -28 I -7 1 I I 22 I I I 43' I I 64 I I I 85 
Week Week -4 Wee k 1 I Week 2 I Week 3 I Week 4 I Week 5 I Wee k 6 Week 7 I Wee k 8 I Wee k 9 I Week 10 I Week 11 I Week 12 
Study medication (active or placebo) will be admin istered as 1 capsule in the morning and 1 capsule in the even ing appro ximately 12 hours apart. 
M: Morning Dose (in mg d6-DM/mg QJ 
E : Evening Dose (in mg d6-DM/mg Q) 
Visit 4 (Day 43) stratification is based on treatment response criteria followed by Re-Randomization . 
Al, A2 are the Stage 1 data for patients who are randomized to Placebo/Placebo and Placebo/AVP-786 , respectively . 
6.2 Study Drug Administration 
Study medication will be administered orally BID throughout the study. 
Patients randomized to receive active drug will start with  mg of d6-DM and  mg of Q 
(AVP-786 ) once a day (QD) for the first 7 days of the study in the morning and 
matching placebo in the evening. Starting on Day 8, these patients will receive A VP-786 
 BID until their next scheduled visit and starting at Visit 2 (Day 15) their dose will be 
escalated to A VP-786 34/4.9 BID for the duration of the study. 
Patients randomized to receive placebo in Stage 1 will take placebo BID for the entire stage. 
Patients who are re-randomized to placebo will continue to receive placebo BID for the entire 
6-week duration of Stage 2. 
Patients who are re-randomized to A VP-786 at the beginning of Stage 2 will receive 
A VP-786 in the same dose escalating manner as patients in Stage 1. 
Confidential Page 11 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
7 STUDY ENDPOINTS 
7.1 Scales and Questionnaires 
7.1.1 16-Item and 4-Item Negative Symptom Assessments (NSA-16, NSA-4) 
The NSA-16 total score is the primary efficacy measure used in this study, and measures the 
presence, severity, and range of negative symptoms associated with schizophrenia. The 
NSA-16 is performed at Screening, BaselineNisit 1 (Day 1), Visit 3 (Day 22), Visit 4 (Day 
43), Visit 6 (Day 64), and Visit 7/Early Termination (Day 85). 
The NSA-16 consists of 16 items, and uses a 5-factor model to describe negative symptoms: 
Factor Domain 
Communication 
Emotion/ Affect 
Social Involvement 
Motivation 
Retardation 
Total NSA-16 Item Numbers 
1, 2, 3, 4 
5,6, 7 
8, 9, 10 
11, 12, 13, 14 
15, 16 
1-16 Score Range 
4-24 
3-18 
3-18 
4-24 
3 -18 
16-96 
Each item is rated on a 6-point Likert scale from 1 to 6, with detailed descriptions of anchors 
at each point on the scale. The severity scores can be interpreted as follows: 
1 =The behavior being assessed is not reduced or absent as compared to a healthy young 
human. 
2 =The behavior being assessed is minimally reduced, significance is questionable. 
3 =The behavior being assessed is mildly reduced; it might only be noted as reduced by a 
trained rater, but he/she notes a definite reduction. 
4 =The behavior being assessed is moderately reduced; the reduction should be obvious 
to an untrained rater. 
Confidential Page 12 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
5 =The behavior being rated is markedly reduced; this behavior is easily observable and 
definitely interferes with the subject's functioning. 
6 =The behavior being assessed is severely reduced or entirely absent; it is glaring and 
markedly interferes with functioning. 
Furthermore, each item admits a score of 9 ifthe item is not ratable. The NSA-16 total score 
is defined as the sum of all 16 items excluding any items receiving a score of 9. If more than 
3 items are not ratable, the total score cannot be calculated and will be regarded as missing; 
otherwise, the total score will be calculated as 16 times the arithmetic mean of the scores of 
all ratable items, rounded to the nearest tenth. Therefore, the minimum score is 16 and the 
maximum score is 96, with a higher score indicating greater clinical severity of symptoms. 
Additionally, two global ratings are included: a global negative symptoms rating, which is 
scored on the basis of the overall impression of negative symptoms in the patient; and a 
global level of functioning, which represents the clinician's overall assessment of the 
patient's level of functioning, relative to a healthy young adult. Both are scored on the 
following scale: 
1 =No evidence of this symptom/impairment 
2 =Minimal evidence of this symptom/impairment 
3 =Mild evidence of this symptom/impairment 
4 =Moderate evidence of this symptom/impairment, apparent to the casual observer 
5 =Marked evidence of this symptom/impairment, readily apparent to the casual observer 
6 =Severe symptom/impairment, not only obvious but has marked impact on functioning 
7 =Extremely severe symptom/impairment that is incapacitating for the subject. 
The NSA-4 is a subset of the NSA-16, using the following items: (1) restricted speech 
quantity; (2) emotion: reduced range; (3) reduced social drive; (4) reduced interests. 
Therefore, the NSA-4 total score ranges from 4 to 24. 
In addition to the NSA-16 total score as the primary efficacy endpoint, the NSA-16 
individual factor domain scores, global negative symptoms/functioning rating, individual 
item scores, and NSA-4 total score are secondary efficacy endpoints. For each factor 
domain, scores will be calculated only if all items in that domain are rated; otherwise, it will 
be regarded as missing. 
7.1.2 Positive and Negative Syndrome Scale (PANSS) 
The PANSS is a 30-item clinical scale to assess positive and negative symptoms of 
schizophrenia, and is performed at Screening, BaselineNisit 1 (Day 1 ), Visit 3 (Day 22), 
Visit 4 (Day 43), Visit 6 (Day 64), and Visit 7/Early Termination (Day 85). 
Each item is rated on the following scale: 
1 =Absent. 
Confidential Page 13 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
2 =Minimal: questionable or subtle or suspected pathology, or may allude to the extreme 
end of the normal range. 
3 =Mild: presence is clearly established but not pronounced, and interferes little in day-
to-day functioning. 
4 =Moderate: characterizes a symptom which, though representing a serious problem, 
either occurs only occasionally or intrudes on daily life only to a moderate extent. 
5 =Moderate to Severe: indicates marked manifestations that distinct impact on one's 
functioning but are not all-consuming and usually can be contained at will. 
6 =Severe: represents gross pathology that is present very frequently, proves highly 
disruptive to one's life, and often calls for direct supervision. 
7 =Extremely Severe: refers to the most serious level of psychopathology, whereby the 
manifestations drastically interfere in most or all major life functions, typically 
necessitating close supervision and assistance in many areas. 
Therefore, the P ANSS total score range is 30 to 210. Items can be grouped into the 
following subscales with the corresponding score ranges: 
Subscale 
Negative Subscale 
Positive Subscale 
General Psychopathology Subscale 
Prosocial Factors 
Marder Negative Factors 
Excitement Component Item Numbers 
Nl-N7 
Pl -P7 
Gl-G16 
G16, N2, N4, N7, P3, P6 
NI -N4, N6, G7, G16 
P4, P7, G4, G8, G14 Score Range 
7-49 
7-49 
16-112 
6-42 
7-49 
5-35 
The P ANSS total score (N 1 -N7, P 1 - P7, G 1 - G 16), and the P ANSS subscales (positive, 
negative, general psychopathology, prosocial factors, Marder negative factors, excitement 
component) are secondary efficacy endpoints. 
Additionally, the proportion of patients with a reduction of 20% or greater in the PANSS 
total score will be calculated, and is a secondary efficacy endpoint. 
7.1.3 Clinical Global Impression (CGI) Scales 
The CGI was developed to provide a brief, stand-alone assessment of the clinician's view of 
the patient's global functioning prior to and after initiating a study medication. The CGI 
provides an overall clinician-determined summary measure that takes into account all 
available information, including knowledge of the patient's history, psychosocial 
circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability 
to function. The following CGI scores are secondary efficacy endpoints, and each is rated on 
a scale of 1 to 7, with a score of 0 indicating no assessment was performed. 
Confidential Page 14 of52 

Statistical Analysis Plan: 15-A VP-786-202 
7.1.3.l Clinical Global Impression -Severity (CGl-S) 
The CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's 
illness at the time of assessment, relative to the clinician's past experience with patients with 
the same diagnosis . Ratings range on the following scale: 
0 =Not assessed 
1 =Normal, not at all ill 
2 = Borderline ill 
3 =Mildly ill 
4 =Moderately ill 
5 =Markedly ill 
6 =Severely ill 
7 =Among the most extremely ill patients . 
The CGI-S will be performed at BaselineNisit 1 (Day 1), Visit 4 (Day 43), and Visit 7/Early 
Termination (Day 85). A score of 0 will be treated as missing data. 
7.1.3.2 Clinical Global Impression -Change (CGI-C) 
The CGI-C is a 7-point scale that requires the clinician to rate the change of the patient's 
condition at the time of assessment , relative to the clinician's past experience with the 
patient's condition at admission. Ratings range from: 
0 =Not assessed 
1 =Very much improved 
2 =Much improved 
3 = Minimally improved 
4 =No Change 
5 =Minimally worse 
6 =Much worse 
7 =Very much worse. 
The CGI-C will be performed at Visit 4 (Day 43) to reflect changes from BaselineNisit 1 
(Day l); and Visit 7/Early Termination (Day 85) to reflect changes from both Visit 4 (Day 
43) and from BaselineNisit 1(Day1) . A score of 0 will be treated as missing data. 
7.1.3.3 Patient Global Impression -Change (PGIC) 
The PGIC is a 7-point patient-rated scale used to assess treatment response. Ratings range 
from: 
0 =Not assessed 
Confidential Page 15 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
1 =Very much improved 
2 =Much improved 
3 =Minimally improved 
4 =No Change 
5 =Minimally worse 
6 =Much worse 
7 =Very much worse. 
The PGIC will be performed at Visit 4 (Day 43) and Visit 7/Early Termination (Day 85), in 
both instances reflecting changes from BaselineNisit 1 (Day 1 ). A score of 0 will be treated 
as missing data. 
7.1.4 Calgary Depression Scale for Schizophrenia (CDSS) 
The CDSS is a 9-item scale derived from the Hamilton Depression Scale (Ham-D), that is 
designed to assess depression specifically in patients with schizophrenia . Each item on the 
scale is scored as: 0 (absent); 1 (mild); 2 (moderate); 3 (severe). The CDSS score is 
obtained by adding each of the item scores; therefore ranges from 0 to 27. The CDSS will be 
performed at Screening, BaselineNisit 1 (Day 1), Visit 3 (Day 22), Visit 4 (Day 43), Visit 6 
(Day 64), and Visit 7/Early Termination (Day 85). The CDSS total score is a secondary 
efficacy endpoint. 
7.1.5 Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) 
The MCCB assesses cognitive change in trials of cognitive-enhancing agents in 
schizophrenia, and includes 10 tests that measure 7 cognitive domains: 
1. Speed of processing 5. Visual learning 
2. Attention/vigilance 6. Reasoning and problem solving 
3. Working memory 7. Social cognition 
4. Verbal learning 
The MCCB evaluation will be performed at Screening, BaselineNisit 1 (Day 1 ), Visit 4 (Day 
43), and Visit 7/Early Termination (Day 85). Alternate versions of the battery will be used at 
different visits to decrease the learning confound. 
The composite score (T-score) is the secondary efficacy endpoint, with higher values 
indicating better cognitive performance. 
7.1.6 Effort Expenditure for Reward Task (EEfRT) 
The EEfRT is a multi-trial computerized task in which participants are given an opportunity 
on each trial to choose between 2 tasks that differ in difficulty level and are associated with 
varying levels of monetary reward. This task examines willingness to expend physical effort 
(button pressing) in pursuit of varying amounts of monetary reward. 
Confidential Page 16 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
The ratio of hard task choices to the total number of trials, as well as the difference in 
proportion of hard-task choices for high effort vs. low effort trials will be the outcome 
measures for negative symptoms, and are secondary efficacy endpoints. The EEfRT 
evaluation will be performed at BaselineNisit 1 (Day 1), Visit 4 (Day 43), and Visit 7/Early 
Termination (Day 85). 
 
 
7.1.8 Mini International Neuropsychiatric Interview (M.I.N.I.) Version 6.0.0 
The M.I.N.I. is an interview developed by psychiatrists and clinicians for psychiatric 
disorders and has an administration time of approximately 15 minutes. 
The interview is divided into 15 categories, which are listed below: 
• Major depressive episode • Substance dependence/abuse (non-
• Suicidality alcohol) 
• Manic and hypomanic episodes • Psychotic disorders and mood 
• Panic disorder disorder with psychotic features 
• Anorexia nervosa • Agoraphobia • Bulimia nervosa • Social phobia • Generalized anxiety disorder • Obsessive-compulsive disorder • Antisocial personality disorder • Posttraumatic stress disorder 
• Alcohol dependence/abuse 
Based on the answers, each category will be classified into a timeframe (e.g., current, past, 
etc.). Missing values will not be imputed. The M.I.N.I. is performed at Screening for the 
purpose of assessing whether the patient meets diagnostic criteria for schizophrenia residual 
type. Results will be presented in the data listings. 
7.1.9 Columbia Suicide Severity Rating Scale (C-SSRS) 
The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior and 
consists of a clinical interview, providing a summary of both suicidal ideation and behavior 
that will be used during treatment to monitor for clinical worsening. 
Confidential Page 17 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
The C-SSRS evaluation is a safety endpoint and will be performed at Screening, 
BaselineNisit 1 (Day 1), Visit 3 (Day 22), Visit 4 (Day 43), Visit 6 (Day 64), and Visit 
7 /Early Termination (Day 85). 
7.1.10 Simpson Angus Scale for Extrapyramidal Symptoms (SAS) 
The SAS is a 10-item evaluation used to assess pseudoparkinsonism. Each item is graded on 
a 5-point severity scale ; thus the total score ranges from 0 to 40, with higher scores indicating 
greater severity of extrapyramidal symptoms . 
The SAS evaluation is a safety endpoint and will be performed at BaselineNisit 1 (Day 1 ), 
Visit 4 (Day 43), and Visit 7/Early Termination (Day 85). 
7.1.11 Barnes Akathisia Scale (BAS) 
The BAS is an assessment of the presence and frequency of akathisia (a movement disorder 
characterized by restlessness and a compulsion to move), as well as its global severity. The 
objective item of the scale measures the clinician's assessment of the patient's restlessness. 
The subjective portion of the scale measures both the patient's awareness ofrestlessness and 
the distress arising from such awareness. Each item is rated on a 4-point scale from 0 to 3, 
and the total score is the sum of the three item scores, thus yielding a total score ranging from 
0 to 9. The Global Clinical Assessment of Akathisia is rated on a 5-point scale from 0 to 4. 
Higher scores indicate greater severity of symptoms. 
The BAS evaluation is a safety endpoint and will be performed at BaselineNisit 1 (Day 1 ), 
Visit 4 (Day 43), and Visit 7/Early Termination (Day 85). 
7.1.12 Abnormal Involuntary Movements Scale (AIMS) 
The AIMS is a 12-item scale to assess dyskinesia. Items related to the severity of orofacial, 
extremity, and trunk movements, global judgment about incapacitation, and patient 
awareness are rated using a 5-point scale (0 =None, 1 =Minimal, 2 =Mild , 3 =Moderate, 4 
= Severe). Two items related to dental status are scored using "yes/no" responses. 
The BAS evaluation will be performed at BaselineNisit 1 (Day 1), Visit 4 (Day 43), and 
Visit 7/Early Termination (Day 85). 
7.2 Efficacy Endpoints 
The primary efficacy endpoint is the change from baseline (CFBL) in the NSA-16 total 
score. 
Confidential Page 18 of52 

Statistical Analysis Plan: 15-AVP-786-202 
Secondary endpoints are the CFBL (or actual scores for the CGI-C and PGIC) in the scores 
of the assessments listed below (and described above): 
• PANSS total score, PANSS subscales (positive, negative, general psychopathology, 
Marder negative factors, excitement component, and prosocial factors) 
• NSA-16 factor domains, global symptom/functioning score, individual items, and 
NSA-4 
• MCCB composite score 
• CGI-S, CGI-C, and PGIC scores 
• CDSS total score 
• EEfR T score 
In addition, the following secondary endpoint will be calculated: 
• Proportion of patients with a reduction of 20% or greater in the P ANSS total score 
7.3 Safety Endpoints 
Safety and tolerability measurements will include: adverse events (AEs), vital signs, weight, 
urine pregnancy tests, clinical laboratory assessments, resting 12-lead ECGs, Columbia 
Suicide Severity Rating Scale (C-SSRS), Abnormal Involuntary Movements Scale (AIMS), 
Barnes Akathisia Scale (BAS), and Simpson Angus Scale for Extrapyramidal Symptoms 
(SAS). 
7.4 Pharmacokinetic,  Parameters 
Plasma concentrations of d6-DM, its metabolites, Q, and anti psychotic medications will be 
assessed at BaselineNisit 1 (Day 1, post-dose), Visit 4 (Day 43), and Visit 7/Early 
Termination (Day 85). Corresponding Cmax and AUC values will be estimated. 
8 ANALYSIS POPULATIONS 
A summary table containing the number of patients in each of the populations described 
below will be provided. 
Confidential Page 19 of52 

Statistical Analysis Plan: 15-A VP-786-202 
8.1 Modified Intent-to-Treat (mITT) Population 
The mITT Population will be used to analyze treatment efficacy according to the SPCD 
design. Due to the study design, the patients included in the population are determined 
separately for Stage 1 and Stage 2, although the Stage 2 group will be a subset of the Stage 1 
group. The population is defined below: 
• Stage 1: All patients randomized in Stage 1 who had at least one post-baseline NSA-
16 total score efficacy assessment in Stage 1. 
• Stage 2: All patients who were re-randomized into Stage 2 (regardless of Stage 1 
treatment group) and had at least one NSA-16 total score efficacy assessment in Stage 
2 (after Week 6Nisit 4) 
When implementing changes in Protocol Amendment 4, the IRT vendor who carried out the 
IVRS found that 14 Stage 1 Placebo patients were re-randomized for Stage 2 at Week 3 
instead of Week 6. These 14 patients with randomization error are excluded from the mITT 
analysis population. 
Confidential Page 20 of52 

Statistical Analysis Plan: 15-A VP-786-202 
8.3 Safety Population 
The safety population will be used for all safety analyses. It includes all patients who 
received at least one dose of study medication. 
Confidential Page 21 of52 

Statistical Analysis Plan: 15-A VP-786-202 
9 OVERALL STATISTICAL CONSIDERATIONS 
9.1 Definition of Baseline 
Baseline is generally defined as the last assessment prior to the first dose of study drug, but 
will vary depending on the analysis, population, treatment group, and parameter. See below 
for specific considerations: 
• For the primary efficacy analysis and secondary efficacy analyses on the mITT or PP 
populations, Stage 1 Baseline is the last assessment prior to first dose (or prior to 
randomization date, for patients who did not take study medication), which is 
typically Day 1. Stage 2 Baseline is the Visit 4 (Week 6) assessment 
(re-randomization visit). Note that Stage 2 Baseline only applies to patients who 
were randomized to placebo in Stage 1 and re-randomized in Stage 2. 
• Baseline for descriptive safety analyses are described below: 
o For patients receiving A VP-786 or placebo for the entire study duration, baseline 
is the last non-missing assessment prior to the first dose of study drug. 
o For patients randomized to placebo then re-randomized to A VP-786, Stage 1 
baseline is the last non-missing assessment to first dose of study drug and Stage 2 
baseline is the last non-missing assessment occurring after Day 1 and prior to 
re-randomization at Week 6. 
9.2 Definition of End of Treatment 
End of treatment is defined as the last value for a given patient, whenever it occurred 
(including Stage 1 values) . This terminology will not be used ifreferring to analysis that is 
done by study stage. 
9.3 Change from Baseline 
Change from baseline (CFBL) will always be calculated as (post-baseline -baseline). It will 
be calculated for patients with both a baseline and post-baseline value as applicable. 
If a baseline value has not been recorded for a parameter, then CFBL will not be calculated 
for that parameter, and the patient will be excluded from CFBL analysis. 
Percent CFBL, when needed, is the CFBL divided by the baseline value multiplied by 100%. 
Patients with a value of 0 at baseline cannot have percent CFBL calculated. 
9.4 Visit Windows 
Data at scheduled visits will be assigned to analysis visits as defined in the Visit Window 
tables below, to ensure that all visits have the potential to be included in the summaries. 
Confidential Page 22 of52 

Statistical Analysis Plan: 15-A VP-786-202 
Visit windows will be used to classify unscheduled and early termination visits. If 2 or more 
visits occur within the same analysis window, the value closest to the target day will be 
summarized. If the assessments are the same distance from the target day, the latest one will 
be used. 
Separate visit window tables are provided based on how frequently the assessments were 
done. Each table is also divided into patients who have advanced to Stage 2 and those that 
have not. 
Table 2. Visit Windows for Assessments Done at Baseline and Weeks 2, 3, 6, 8, 9, 12 
StageNisit Target Study Days (Patients Study Days (Patients Not 
Day Advancing to Stage 2) Advancing to Stage 2) 
Stage 1 Lower Bound Upper Bound Lower Bound Upper Bound 
Week 2 (Visit 2) 15 2 18 2 18 
Week 3 (Visit 3) 22 19 ReR-2 19 32 
Week 6 (Visit 4) 43 ReR-1 ReR 33 day of last visit 
Stage 2 
Stage 2 Baseline ReR-1 ReR NIA NIA 
Week 8 (Visit 5) 57 ReR+ 1 60 NIA NIA 
Week 9 (Visit 6) 64 61 74 NIA NIA 
Week 12 (Visit 7) 85 75 day of last visit NIA NIA 
NIA= Not applicable . ReR = re-randomization visit day. 
Table 3. Visit Windows for Assessments Done at Baseline and Weeks 3, 6, 9, and 12 
StageNisit Target Study Days (Patients Study Days (Patients Not 
Day Advancing to Stage 2) Advancing to Stage 2) 
Stage 1 Lower Bound Upper Bound Lower Bound Upper Bound 
Week 3 (Visit 3) 22 2 ReR-2 2 32 
Week 6 (Visit 4) 43 ReR-1 ReR 33 day of last visit 
Stage 2 
Stage 2 Baseline ReR-1 ReR NIA NIA 
Week 9 (Visit 6) 64 ReR+ l 74 NIA NIA 
Week 12 (Visit 7) 85 75 day of last visit NIA NIA 
NIA= Not applicable . ReR =re-randomization visit day. 
Table 4. Visit Windows for Assessments Done at Baseline, Week 6, and Week 12 Only 
StageNisit Target Study Days (Patients Study Days (Patients Not 
Day Advancing to Stage 2) Advancing to Stage 2) 
Stage 1 Lower Bound Upper Bound Lower Bound Upper Bound 
Week 6 (Visit 4) 43 2 ReR 2 day of last visit 
Stage 2 
Stage 2 Baseline ReR-1 ReR NIA NIA 
Week 12 (Visit 7) 85 ReR+ l day of last visit NIA NIA 
NIA= Not applicable . ReR =re-randomization visit day. 
Confidential Page 23 of52 

Statistical Analysis Plan: 15-A VP-786-202 
Table 2 applies to Vital Signs, Weight, C-SSRS; Table 3 applies to Pregnancy test, NSA-16, 
PANSS, CDSS; and Table 4 applies to ECG, Chemistry/Hematology/Urinalysis, SGA 
plasma concentrations, Study drug plasma concentrations, MCCB, CGI-S, CGI-C, PGIC, 
EEfRT, AIMS, BAS, SAS, . 
9.5 Handling of Missing Data 
Missing data will be handled differently depending on the parameter and analysis. Note that 
analyses done on 'observed cases' will not follow any imputation rules below. See below for 
considerations: 
• Missing baseline values will not be imputed in any situation. 
• For SPCD  efficacy analyses (excluding observed cases 
analyses), missing data will be imputed by Last Observation Carried Forward (LOCF) 
within a study stage. For example, missing assessments from Week 12 (Visit 7) can 
be imputed with the value from Week 9 (Visit 6) but not from Week 3 (Visit 2). Note 
that if Week 3 or Week 6 data are missing for an mITT patient, then baseline will be 
carried forward. Likewise, Stage 2 baseline will be carried forward if Week 9 data 
are missing for patients with Stage 2 data. No imputation will be done for patients 
without data in Stage 2. 
• For any safety assessments of patients without a Week 12 safety endpoint assessment, 
the last non-missing post-baseline observation will be used as the end of treatment 
value. 
• Missing post-baseline values for by-visit safety data will be summarized using the 
Visit Windows from Section 9.4. If a value is not available within a given window, 
no imputation will be done. 
• Missing data for AE relationship will be imputed as "Related." 
• Rules for partial dates are described in Appendix 3. These will apply to concomitant 
medications when applicable. 
9.6 Treatment Misallocations 
Efficacy data will be summarized "as randomized," meaning the patient will be summarized 
under the treatment they were randomized to, regardless of what treatment was actually 
received. 
Safety data will be summarized "as treated," meaning the patient will be summarized based 
on the treatment that was actually received. 
Confidential Page 24 of52 

Statistical Analysis Plan: 15-A VP-786-202 
9.7 Summary Statistics 
Quantitative displays will be summarized using descriptive statistics. The mean, standard 
deviation, median, minimum, and maximum will be provided. Decimal precision will be 
based on the mean value. The median contains the same number of decimal places as the 
mean, the standard deviation contains one more decimal place, and the minimum and 
maximum contain one less decimal place. The mean will typically have one more decimal 
place than the raw values but if necessary, decimal precision for the mean will be provided in 
the table specifications. 
9.8 Data Listings 
Unless otherwise specified, data listings will be provided on observed values and calculated 
PK parameters. Efficacy listings for the primary and secondary endpoints will include 
analysis flags and/or imputations to show which values were used in the summary tables.  
 
 Listings will be provided to serve as support for all summary tables 
or figures. 
9.9 Graphical Displays 
Supporting figures may be used for some efficacy, PK or safety analyses in addition to the 
summary tables. Details regarding the content, layout, and structure of figures will be 
provided in the table specifications. 
9.10 Hypothesis Testing 
All statistical testing will be 2-sided and performed at the 0.05 significance level. 
9.11 Multiplicity of Secondary Endpoints 
No adjustments will be made for testing multiple secondary outcome measures. Since it is 
possible that some significant results could occur by chance alone, undue consideration will 
not be given to isolated significant differences; rather, interpretations will be made based on 
patterns of significant differences and their consistency with the primary endpoint analysis. 
10 EFFICACY STATISTICAL ANALYSIS METHODS 
The study schematic in Figure 1 can be referenced to identify treatment groups that are 
described in the subsequent efficacy sections. 
10.1 Primary Efficacy: SPCD MMRM (Mixed-Model Repeated Measures) 
The primary efficacy endpoint (CFBL in NSA-16 total score), will be analyzed using a 
weighted test statistic with the treatment effects in each stage estimated by likelihood-based 
mixed-model repeated measures (MMRM) analysis on the observed data (Chen et al, 2011). 
This model will be run on the mITT population, which will include observed data from 
Confidential Page 25 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
Stage 1 mITT patients and from the Stage 1 Placebo Non-Responder Subset in Stage 2. Visit 
windows will be applied for unscheduled or early termination visits. The null hypothesis to 
be tested is that there will be no difference in the CFBL in NSA-16 total score between AVP-
786 and placebo in Stage 1 and Stage 2. 
Per the SPCD, separate MMRMs will be run using data from Stage 1 and Stage 2. Stage 1 
data (CFBL to Week 6) will contain data for all mITT Stage 1 patients and will compare 
study segments A and B from the study schematic. Stage 2 data (change from Week 6 to end 
of treatment) will be used for patients in the Stage 1 Placebo Non-responders of the Stage 2 
mITT population and will use study segments E and F. Stage 1 treatment effect will be 
estimated by Week 6 treatment difference and the Stage 2 treatment effect will be estimated 
by the Week 12 treatment difference. The model will include terms for treatment, visit, 
treatment-by-visit interaction, baseline NSA-16 value and baseline-by-visit interaction. An 
unstructured covariance matrix (UN) will be used. However, ifthere are convergence 
problems, analyses with a first-order autoregressive covariance structure (AR[l]) or the 
compound symmetry covariance structure (CS) will be used. The SAS model statement is 
provided below: 
The parameter estimates at Week 6 (Stage 1) and Week 12 (Stage 2) will be used in each 
stage to come up with a combined weighted test statistic, ZMMRM that is described in Chen, et 
al (2011 ). The formula for the test statistic is given below: 
W {j(l) + (1 -W) {j(Z) 
ZMMRM = ---;::=========== j w2 Var({JC1)) + (1 -w)2 Vclr({JC2)) 
where a weight ofw =  is used for Stage 1, which means a weight of 1-w =  is used 
for Stage 2. The estimated treatment effects {}Cl), {}CZ) and squared standard errors 
Var({}Cl)), Var({}C2)) of each treatment stage are obtained directly from the model output. 
The test statistic will be used to come up with a 2-sided p-value for the hypothesis test, 
shown below: 
p_value=2*(1-probnorm(abs(ZMMRM))); 
Confidential Page 26 of52 

Statistical Analysis Plan: 15-A VP-786-202 
Confidential Page 27 of52 

Statistical Analysis Plan: 15-A VP-786-202 
10.3 Secondary Efficacy Analysis 
The following secondary endpoints will be analyzed in this study, using the methodologies 
described in the following subsections: 
• P ANSS total score 
• PANSS subscales (positive, negative, general psychopathology, Marder negative 
factors, excitement component, pro-social factors) 
• NSA-16 factor domains, global symptom/functioning score, individual items, global 
negative symptoms rating, and NSA-4 total score 
• Proportion of patients with a reduction of 20% or greater in the P ANSS total score 
• MCCB composite score 
• CGI-S, CGI-C, and PGIC scores 
• CDSS score 
• EEfRT score  
Confidential Page 28 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
10.3.1 Secondary SPCD MMRM and SPCD OLS ANCOV A 
The CFBL for all quantitative secondary endpoints listed above (except the CGI-C and the 
PGIC) will be analyzed using the OLS ANCOV A method as described in Section 10.2.1. 
The mITT population (Stage 1 plus the Stage 1 Placebo Non-Responders for Stage 2) will be 
used for these analyses. LOCF within a study stage will be used for missing values at Week 
6 or Week 12. In addition, the secondary endpoints listed above measured by NSA-16, 
PANSS and CDSS (which were assessed at Baseline, Week 3, 6, 9 and 12) will also be 
analyzed using the SPCD MMRM method as described in Section 10.1. 
For the CGI-C and the PGIC, an ANCOV A model with treatment as a factor and baseline 
NSA-16 total score as a covariate will be run. Note that baseline NSA-16 total score depends 
on the study stage and is defined in Section 9 .1. All model considerations will be the same as 
the primary parameters as described in Section 10.1. 
10.3.2 P ANSS Response Analysis 
The number and percent of patients who have favorable treatment responses according to the 
PANSS will be summarized at Week 6 and Week 12 using the mITT population (Stage 1 
plus the Stage 1 Placebo Non-responders in Stage 2). The following category will be used to 
classify patients: 
• Response: patients with at least a 20% reduction in the P ANSS total score. 
The number and percent of responders will be provided by stage and treatment group. LOCF 
will be used for patients missing data. Overall Stage 1 and 2 treatment differences will be 
tested via SPCD 1 degree of freedom (DOF) score test assuming Stage 2 and 1 treatment 
effect ratio p=l (A. Ivanova, et al, 2011). In addition, the treatment effect will also be tested 
at each visit by Chi-square test or Fisher's Exact (if the expected cell counts are< 5). 
Confidential Page 29 of52 

Statistical Analysis Plan: 15-A VP-786-202 
Confidential Page 30 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
Confidential Page 31of52 

Statistical Analysis Plan: 15-A VP-786-202 
Confidential Page 32 of52 

Statistical Analysis Plan: 15-A VP-786-202 
11 SAFETY STATISTICAL ANALYSIS METHODS 
Safety will be assessed through the analysis of AEs, physical and neurological examinations, 
vital signs, clinical laboratory assessments, ECGs, the C-SSRS, the SAS, the BAS, and the 
AIMS. All Safety analyses will be completed on the Safety Population. 
Unless otherwise specified, safety analyses that include summaries of number and percent 
(e.g., AEs) will be displayed using the following treatment groups: 
• Placebo/Placebo: patients receiving Placebo/Placebo during the study (study segment 
Al, C and E ). Note that patients randomized to Placebo/AVP-786 but dropped out in 
Stage 1 (part of A2) are not included in this population . Instead, these will be 
summarized under the 'All Placebo' treatment group. 
• A VP-786/ A VP-786: patients receiving A VP-786 for the entire duration of the study 
(Band G). 
• Placebo/ A VP-786: patients who switched from placebo to A VP-786. This group 
will be further divided into data that occurred while on placebo (A) and data that 
occurred while on AVP-786 (D and F). 
• All Placebo: This includes data from the stages when patients received placebo (A, 
C, and E). 
• All A VP-786: This includes data from the stages when patients received A VP-786 
(B, D, F, and G). 
Confidential Page 33 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
All Placebo and All A VP-786 treatment groups summarize the safety information for their 
corresponding treatment group under 6 week or 12 week treatment exposure in either Stage 
1, Stage 2, or both. 
For quantitative summaries (e.g., ECGs, labs), the All Placebo and All AVP-786 groups will 
not be included. As noted in Section 9 .1, baseline for safety assessments (excluding shift 
tables) is the last non-missing value prior to taking study drug at baseline. For those 
switching from placebo to A VP-786, baseline is the last non-missing value prior to taking 
AVP-786. 
11.1 Adverse Events 
Adverse event tables (except the AE overview table) will only include summaries ofTEAEs. 
Treatment-emergent adverse events are defined as AEs which first occur, or worsen, after the 
first dose of study medication and within 3 0 days after the permanent discontinuation of the 
study medication (i.e., first dose date :SAE start date :S last dose date+ 30 days). 
An overview table containing the number and percent of the following will be included: 
• Number of total AEs, TEAEs, and deaths 
• Incidence of patients with at least one TEAE, drug-related TEAE, serious AE (SAE), 
drug-related SAE, non-serious TEAEs, and death 
• Incidence of patients who discontinued due to TEAE, drug-related TEAE, SAE, and 
drug-related Si'.ill 
• Incidence of deaths and deaths due to drug-related TEAE 
Treatment-emergent adverse events will be summarized by SOC and PT, descending 
frequency of PT, by maximum severity, by dose at onset, and by age group(< 45, 2: 45). 
Summaries of PTs will also be done for those occurring in at least 5% of patients in any 
treatment or study stage. In addition, summaries of patients taking beta blockers at baseline 
will be summarized as described in Section 10.4.6 . 
Adverse events leading to discontinuation will be summarized by SOC and PT. Drug-related 
AEs will be summarized by SOC and PT and in descending frequency of PT. 
Time to onset for common TEAEs (as defined below) will be summarized descriptively for 
each of these events. In addition, summary stats for the duration and percentage of total 
study days will be provided for each AE. The number and percent of patients with 
recurrences will also be given. 
Serious adverse events will be summarized by SOC and PT and will include a summary of 
drug-related events. 
Below are the rules to follow for AE summaries: 
Confidential Page 34 of52 

Statistical Analysis Plan: 15-A VP-786-202 
• For patients who took A VP-786/ A VP-786 or Placebo/Placebo: If a patient has 
multiple AEs within the same SOC or PT, the patient will only be counted once 
within a level of Medical Dictionary for Regulatory Activities (MedDRA). 
• For patients who switched from placebo to AVP-786: If the same AE starts in both 
study stages, it should be counted under both placebo and A VP-786. 
• A drug-related AE is defined as an AE with an assigned relationship of "possibly 
related," "related," or missing. 
• When assessing severity, if a patient has 2 TEAEs within a study stage, the TEAE 
with the worst severity will be chosen. AEs with missing severity will be excluded 
from summaries of AE by severity. 
• For dose at onset summaries, patients are counted only once within a dose, but can be 
counted in multiple dose groups if the same AE occurred while on different doses. 
• A common TEAE is defined as a TEAE an incidence of2: 3% in the All AVP-786 
treatment group AND 2: 2 times the incidence of the All Placebo treatment group. 
• Time to onset will be calculated in days as (AE start date -first dose date). For 
patients who switched from placebo to A VP-786, the following rules will apply: 
o If an AE occurs when the patient is on A VP-786, time to onset is calculated as 
(AE start date -re-randomization date). This includes the time on A VP-786 only. 
o If the same AE occurs while the patient is on placebo and then again when the 
patient is on A VP-786, the AE will be counted in both groups, and first dose date 
will be defined as the first dose of placebo or first dose of A VP-786, depending 
on which treatment the patient was on when the AE occurred. 
• Duration of AE is generally defined as (AE end date-AE start date+ 1). Duration 
will be calculated for placebo and A VP-786 separately. Below are some additional 
considerations for AE duration: 
o If the patient has an AE on placebo that has not ended when the patient takes the 
last dose of placebo (either due to switching to A VP-786 or end of study), AE end 
date is defined as the last dose of placebo. 
o If the patient has an AE on A VP-786 that has not ended when the patient ends the 
study, AE end date is defined as the last dose of study drug. 
o If the same AE occurs more than once while the patient is on the same treatment, 
duration will be the sum of the individual AE durations. 
• For a given patient, percentage of total study days is defined as total duration (as 
defined above) divided by (last dose date -first dose date+ l) x 100%. 
• Recurrence is defined as a new report of the same TEAE with a new AE start date 
within a given treatment. An AE that occurs for a patient on placebo and then again 
on A VP-786 will not be considered a recurrent event. 
AEs will be coded using MedDRA version 18.1. 
Confidential Page 35 of52 

Statistical Analysis Plan: 15-A VP-786-202 
11.2 Clinical Laboratory Assessments 
Clinical labs will be reported for hematology, chemistry and urinalysis. Labs are collected at 
Screening, Week 6 and Week 12, and will be summarized by visit, by stage and for the 
Placebo/Placebo and A VP-786/ A VP-786 groups as described below. 
The following parameters will be summarized descriptively through CFBL and percent 
CFBL for numeric values. If a parameter is categorical, it will be listed only. 
• Chemistry: calcium, magnesium, phosphorus, glucose, sodium, potassium, chloride, 
carbon dioxide, blood urea nitrogen (BUN), serum creatinine, uric acid, albumin, total 
bilirubin, alkaline phosphatase, lactate dehydrogenase (LDH), aspartate 
aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), alanine 
aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT), creatine kinase 
(CK), gamma-glutamyl transferase (GGT), triglycerides, total protein, total 
cholesterol, and glycosylated hemoglobin (HbAlc, at Screening and Visit 7). 
• Hematology: red blood cell (RBC) count, hemoglobin, hematocrit, white blood cell 
(WBC) count, neutrophils, bands, lymphocytes, monocytes, eosinophils, basophils, 
platelet count, and morphology 
• Urinalysis: pH, specific gravity, protein, glucose, ketones, bilirubin, urobilinogen, 
nitrites, leucocytes, and blood 
Out-of-range values will be assessed through shift tables. Each lab value will be assessed as 
low, normal or high based on the normal ranges provided by the central lab. Frequencies of 
each combination of shifts will be provided by treatment group. 
Shift tables will be created by stage and for the Stage 1 Placebo, A VP-786, Stage 2 Placebo 
(Stage 1 Placebo re-randomized to Placebo) and Stage 2 A VP-786 (Stage 1 Placebo re-
randomized to A VP-786). In Stage 1, A VP-786 will be compared to placebo and in Stage 2, 
the placebo patients who were re-randomized to either A VP-786 or placebo will be 
compared. Baseline in all shift tables is the last assessment prior to first dose in each stage. 
Last post-baseline visit for Stage 1 is the last assessment prior to or on the Week 6 visit, 
while the last post-baseline visit in Stage 2 and the Placebo/Placebo, A VP-786/ A VP-786 
groups is the last assessment, whenever it occurred.  
 
Potentially clinically significant (PCS) tables will also be used to summarize out-of-range 
values. The PCS values are found in Table 5. The number and percent of patients meeting 
the criteria below will be summarized by treatment group. Summaries will be given for any 
time post-baseline. The denominator for the percentages will be the number of patients who 
had a post-baseline assessment for each parameter. 
Confidential Page 36 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
Table 5. Lab PCS Criteria 
Laboratory Low PCS High PCS Laboratory Low High PCS Unit Unit PCS Parameter Criteria Criteria Parameter Criteria Criteria 
Chemistry 
Albumin g/L :S26 ~ 60 GGT U/L None ~ 60 
Alkaline U/L None ~3xULN Glucose mmol/L :S 2.775 ~ 11.1 Phosphatase 
ALT (SGPT) U/L None ~3xULN LDH U/L None ~3xULN 
AST (SGOT) U/L None ~3xULN Magnesium mmol/L < 0.37 > 1.23 
Bilirubin µmol/L None ~ I.5xULN Phosphate mmol/L :S 0.4522 > 3.88 
BUN mmol/L None ~ 10.71 Potassium mmol/L :S3.0 ~ 5.5 
Calcium mmol/L :S 1.75 ~ 3.0 Protein g/L :S 50 ~ 100 
Carbon mmol/L :S 9 >40 Sodium mmol/L :S 130 ~ 155 Dioxide 
Chloride mmol/L :S 85 ~ 120 Triglycerides mmol/L None > 3.39 
Cholesterol mmol/L None ~ 7.77 Uric acid µmol/L None ~ 624.54 (Male) 
Creatine U/L None ~3xULN Uric acid µmol/L None ~ 505.58 Kinase (Female) 
Creatinine µmol/L None > 132.6 HbAlc % None 6.5% 
Hematology 
Hemoglobin g/L < 100 > 180 Monocytes xl09/L None > 1 
Hematocrit proportion < 0.3 > 0.5 Monocytes/ % None ~ 15 of 1.0 Leukocytes 
Basophils xl09/L None > 0.3 Neutrophils/ % :S 15 None Leukocytes 
Eosinophils/ % None ~ 10 Leukocytes xl09/L :S 2.8 ~16 Leukocytes 
Lymphocytes xl09/L :S 0.5 >4 Erythrocytes x 1012/L :S2.5 ~ 7.0 
Lymphocytes/ % :S 10 ~ 60 Platelet xl09/L :S 100 ~ 700 Leukocytes Count 
Over the course of the study, there may be some lab tests performed that were not mentioned 
in the protocol. These tests will not be summarized but will be included in the listings and 
flagged as non-protocol tests. 
11.3 ECGs 
Electrocardiograms will be assessed by a central reader and will be recorded at the following 
visits: 
• Screening (triplicate readings) 
• BaselineNisit I (Day 1) (pre-dose) 
• BaselineNisit I (Day I) (2-3 hours post-dose) 
• Visit 4/Week 6 (Day 43) (pre-dose) 
Confidential Page 37 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
• Visit 4/Week 6 (Day 43) (2-3 hours post-dose) 
• Visit 7/Early Termination (Day 85) (pre-dose) 
• Visit 7/Early Termination (Day 85) (2-3 hours post-dose) 
The following quantitative parameters will be reported by the central reader: heart rate, PR 
interval, QRS duration , QT interval (uncorrected) , and QT interval with Fridericia's 
correction (QTcF) . Change from baseline and percent change from baseline will be 
calculated for each parameter and summarized by the treatment groups mentioned in 
Section 11. Note that for patients who switched from placebo to A VP-786, baseline is 
defined as described in Section 9 .1. 
In addition, since ECGs are recorded pre- and post-dose at Baseline , Week 6 and Week 12, 
change from pre- to post-dose will be summarized at these visits. 
PR interval and QTcF will be further investigated through PCS tables , for which the criteria 
are found in Table 6 below. The number and percent of patients meeting the criteria below 
will be summarized by treatment group. Summaries will be given for both overall (i.e., any 
time post-baseline) and by visit. For QTcF, males and females will be assessed separately. 
Patients will be included in all categories for which they qualify. For criteria on the "Actual" 
values, the denominator for the percentages is the number of patients who had a post-baseline 
assessment for each parameter. For criteria on the change, the denominator is the number of 
patients who had a baseline and post-baseline assessment. 
Table 6. ECG PCS Criteria 
ECG Parameter Sex Actual or Change PCS Criteria 
> 200 to :S 220, 
PR Interval (msec) Both Actual > 220 to :S 250, 
>250 
> 450 to ::; 480, 
Males Actual > 480 to ::; 500, 
> 500 
QTcF (msec) > 460 to :S 485, 
Females Actual > 485 to :S 500, 
> 500 
Both Change from baseline (increase) :::: 30,:::: 60 
ECG overall interpretations will be summarized by the number and percent that were normal 
or abnormal. The interpretations by the cardiologist (i.e., central ECG , iCardiac) will be used 
for these summaries. For females, iCardiac uses QTcF > 460 msec to ::::; 485 msec for PCS 
criteria and this will be flagged in corresponding tables and listings. The listings will provide 
all interpretations and corresponding details. 
11.4 Vital Signs 
Vital signs will be assessed at all visits. Orthostatic blood pressure is taken at Screening and 
supine/semi-recumbent blood pressure is taken at all subsequent visits. All 
Confidential Page 38 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
supine/semi-recumbent measurements are recorded twice, so the mean of the 2 measurements 
will be taken and used for all summaries mentioned below. The following parameters 
recorded in the supine/semi-recumbent positions will be summarized: systolic blood 
pressure (SBP), diastolic blood pressure (DBP), heart rate. Weight will also be summarized. 
These parameters will be summarized through CFBL and percent CFBL in similar fashion as 
the ECG parameters. For heart rate, SBP and DBP, box plots by visit will be presented for 
Stage 1  safety population. 
Vital signs will also be assessed through PCS criteria, which are given in Table 7. Patients 
will be counted if they meet the criteria below at any time post-baseline. The definition of 
baseline is consistent with those for ECG parameters. The denominators are the number of 
patients with both a baseline and post-baseline assessment. 
Table 7. Vital Sign PCS Criteria 
Vital Sign 
Parameter 
SBP (mmHg) 
DBP (mmHg) 
Pulse (bpm) 
SBP and pulse 
DBP and pulse High Values 
> 180 AND 2: 20 increase from baseline 
2: I 05 AND 2: 15 increase from baseline 
2: 120 AND 2: 15 increase from baseline 
SBP 2: I 0 increase from baseline AND pulse 2: 5 
increase from baseline 
DBP 2: 5 increase from baseline AND pulse 2: 5 
increase from baseline 
All vital sign parameters will be included in the listings. 
11.5 Physical and Neurological Exams Low Values 
:S 90 AND 2: 20 decrease from baseline 
:S 50 AND 2: 15 decrease from baseline 
:S 50 AND 2: 15 decrease from baseline 
Not Applicable 
Not Applicable 
Physical and neurological exams are assessed at Screening and will be listed. 
11.6 C-SSRS 
Scoring for the C-SSRS will be analyzed using the following indicators: 
• Ideation severity: each of the 5 questions regarding type of ideation (yes/no) 
• Intensity of most severe ideation: a sum of the 5 intensity items 
• Suicidal behavior types: each of the 4 suicidal behavior types (yes/no) 
• Suicidal behavior: suicidal behavior question 
• Actual lethality: actual lethality question (0-5 scale) on most lethal attempt 
• Potential lethality: potential lethality question (0-2 scale) on most lethal attempt 
The individual questions listed above that have yes/no responses will be summarized by 
treatment group and visit using number and percent. 
Intensity of most or severe ideation will be summarized descriptive by treatment group and 
visit. 
Confidential Page 39 of52 

Statistical Analysis Plan: 15-A VP-786-202 
Items that contain an ordinal response will be summarized both through descriptive statistics 
and number and percent. 
All C-SSRS data, including individual text descriptions (included as part of some questions), 
will be included in the listings. 
11.7 Simpson Angus Scale for Extrapyramidal Symptoms (SAS) 
The individual items, as well as the total score, will be summarized. Descriptive statistics 
will be provided by treatment group and visit for males and females separately, as well as 
both sexes overall. For each item, a shift table of the number and percent of patients in each 
score (0 to 4) from Baseline to Week 6 and Baseline to Week 12 will be summarized overall 
and for males and females separately. 
11.8 Barnes Akathisia Scale (BAS) 
The objective assessment, subjective awareness, subjective distress, and global clinical 
assessment, as well as the total score, will be summarized. Descriptive statistics will be 
provided by treatment group and visit for males and females separately, as well as both sexes 
overall. Shift tables of the number and percent of patients of the total score and the global 
clinical assessment will be presented for Baseline to Week 6 and Baseline to Week 12, for 
males and females separately as well as both sexes overall. 
11.9 Abnormal Involuntary Movement Scale (AIMS) 
The following table represents the scores to be calculated and summarized: 
Subscale/Score Item Numbers Score Range 
Orofacial Movements 1, 2, 3, 4 0-16 
Extremity Movements 5, 6 0-8 
Trunk Movements 7 0-4 
Global Judgment 8, 9, 10 0-12 
Dental Status 11, 12 Yes/No 
Observed Movements 1-7 0-28 
Overall Severity 8 0-4 
Descriptive statistics will be provided by treatment group and visit for males and females 
separately, as well as both sexes overall. Shift tables of the number and percent of patients 
will be presented for Baseline to Week 6 and Baseline to Week 12 for the overall severity, 
for males and females separately as well as both sexes overall. 
Confidential Page 40 of52 

Statistical Analysis Plan: 15-A VP-786-202 
12 ADDITIONAL STATISTICAL ANALYSIS METHODS 
12.1 Patient Disposition 
Counts of patient enrollment will provide the number of patients screened along with the 
reason for screen failures. A summary of randomized treatment group by responder status 
will be provided. Patient status will be summarized by the following: 
• Randomized in Stage 1 
• Took study medication 
• Discontinued during each stage 
• Re-randomized to Stage 2 
• Completed study 
Counts will be provided by Stage 1 randomized treatment group based on the study stage. 
Primary reasons for discontinuation will be provided based on the number of patients in the 
treatment group and stage. 
An overall number of patients by stage in the mITT,  and 
Safety populations will be provided. 
12.2 Demographics and Baseline Characteristics 
Demographics will be summarized by randomized treatment group and overall for the mITT, 
and Safety populations. The following characteristics will be summarized. 
• Sex (Male, Female) 
• Race (White, Black or African American, Asian, American Indian or Alaska Native, 
Native Hawaiian or Other Pacific Islander, Other) 
• Ethnicity (Hispanic or Latino, Not Hispanic or Latino) 
• Age 
• Age group(< 55, 2 55) 
• Height 
• Weight 
• Body mass index 
A summary of baseline characteristics will include baseline values of all primary and 
secondary endpoints, in addition to height, weight, and body mass index. These will be 
summarized by randomized treatment group. Additional tables of primary and secondary 
endpoints for placebo non-responders and placebo responders will be created. Stage 2 
baseline will be used for these patients . 
For categorical parameters, the denominators for the percentages are the number of patients 
who had the parameter assessed. 
Confidential Page 41 of52 

Statistical Analysis Plan: 15-A VP-786-202 
12.3 Medical History and Disease Characteristics 
Medical history will be summarized by SOC and PT based on Stage 1 randomization and 
will be presented in the listings. Summary tables will be provided for the frequency and 
percentage of patients by the following subgroups: 
• MCCB score< 30 versus 2: 30 
• Baseline concomitant benzodiazepine, SSRI, and SSNI medication use (Yes/No) 
Additionally, descriptive statistics for the number of years since the onset of schizophrenia, 
and the number of years since the onset of residual schizophrenia, will be presented. In both 
cases, the number of years will be counted relative to the patient's randomization date in 
Stage 1. 
12.4 Exposure and Treatment Compliance 
Duration of exposure will be summarized quantitatively using the number of days on study 
medication for each patient, displayed by treatment group. Summaries will be done for 
Placebo/Placebo, A VP-786/ A VP-786, and each arm of the Placebo/ A VP-786 group. 
Duration for the Placebo/Placebo and A VP-786/ A VP-786 groups will be calculated as (last 
dose date -first dose date+ 1 ). For Stage 1 Placebo/ A VP-786 (placebo portion), duration 
will be calculated from first dose until the day prior to re-randomization, i.e., (re-
randomization date -first dose date). For Stage 2 (A VP-786 portion), duration will be 
calculated from re-randomization to last dose date, i.e., (last dose date -re-randomization 
date+ 1). 
An additional summary of exposure will be provided by dose taken for patients who took 
A VP-786 at any time during the study. The number of days at the specified dose level will 
be summarized. Treatment groups will be A VP-786/ A VP-786 and Placebo/ A VP-786. Since 
the dosing regimen increases after one week on treatment but a visit does not occur for 2 
weeks after starting treatment, it is assumed that each dose level is taken for 7 days, as 
specified in the protocol. Doses summarized will be  mg QD,  mg BID and 34 mg BID. 
The dosing regimen can be found in Figure 1. 
Overall treatment compliance will be calculated as a percentage using the total number of 
capsules that were dispensed and returned. Patients will be grouped into categories of 
< 80%, 80% to 120%, > 120%. Counts will be summed over the visits for each patient to 
calculate an overall compliance value. 
Compliance will be summarized as described above and through descriptive statistics for 
Placebo/Placebo, A VP-786/ A VP-786, and each arm of the Placebo/ A VP-786 group. The 
number of doses taken and number of doses should have taken are necessary to calculate 
compliance. The calculation for number of doses should have taken will be slightly different 
for patients who were randomized vs. those who were not re-randomized, as well as between 
Stage 1 and Stage 2. These differences are provided in the table below. The 3 steps for 
calculating compliance are shown here: 
Confidential Page 42 of52 

Statistical Analysis Plan: 15-A VP-786-202 
I. Doses taken: dispensed amount -returned amount 
2. Doses should have taken: 
Stage 
Stage I 
Stage 2 
Overall Patients Re-randomized 
2 x (re-randomization day -first dose day) 
2 x (last dose day -re-randomization day) +I 
2 x (last dose day -first dose day) + I Patients Not Re-randomized 
2 x (last dose day -first dose day) + I 
NIA 
2 x (last dose day -first dose day) + I 
3. Compliance = (doses taken I doses should have taken) x I 00% 
For the calculations in table above, the formulas are based on the assumption that patients 
take 2 capsules per day except for the last day, in which they only take I. One exception is 
for the Stage I calculation of patients who were re-randomized. For these patients, I is not 
subtracted because they will take 2 capsules on the last day of Stage I. 
The number of capsules taken for kits that were not returned will be imputed to be the 
number of capsules that were dispensed . 
12.5 Prior and Concomitant Medications 
The number and percent of prior and concomitant medications will be provided by the 
treatment groups used for the safety analyses . Prior medication is defined as medication with 
a stop date prior to first dose date. Concomitant medication is defined as a medication with a 
start date on or before the last dose date AND a stop date on or after first dose date. 
Medication that is ongoing at the time of first dose is also considered concomitant. Partial 
dates will be imputed using rules in Appendix 3. 
Prior and concomitant medications will be coded using WHO Drug Dictionary (version 
September 20I5) . Summaries will be provided by anatomical therapeutic chemical 
classification (ATC) and preferred term. 
12.6 Analysis of Pharmacokinetics and Pharmacodynamics 
Confidential Page 43 of 52 

Statistical Analysis Plan: 15-AVP-786-202 
13 ADDITIONAL STATISTICAL CONSIDERATIONS 
13.1 Data Safety Monitoring Board (DSMB) 
There is no DSMB for this study. 
13.2 Changes from Protocol 
When implementing changes in protocol amendment 4, the IRT vendor who carried out the 
IVRS found that 14 Stage 1 Placebo patients were re-randomized for Stage 2 at Week 3 
instead of Week 6. These 14 patients with randomization error are excluded from the mITT 
and ITT analysis population although they satisfied protocol mITT and ITT population 
criteria. Their safety data are summarized under safety population and their efficacy data are 
included in the corresponding data listings. 
Confidential Page 44 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
14 REFERENCES 
Confidential Page 45 of52 

Statistical Analysis Plan: 15-A VP-786-202 
15 APPENDICES 
Confidential Page 46 of52 

Statistical Analysis Plan: 15-A VP-786-202 
Appendix 1 Schedule of Assessments and Procedures 
Stage 1 I Stage 2 
Visit Screening Baseline Phone' Visit22 Visit31 Visit 42 Phone' Visit52 Visit61 Visit Post Exit 
Visit 1 7/ET2•4 Phone' 
PROCEDURE Study Day Day-28 to -7 Day 1 Day8 Day 15 Day22 Day43 Day SO Day57 Day64 Day85 Day 86-90 
Study Week Week-4 to -1 Week 1 Week2 Week3 Week6 Week? Week8 Week9 Week 12 
Informed Consent x 
 x x 
Medical History x 
M.I.N .I. Exam x 
Inclusion and Exclusion x x 
Randomization I (re-x x randomization) 
Physical Examination x 
Resting 12-lead ECG x6 x6 x6 x6 
Chemistry, Hematology, and x x x Urinalysis3 
Pregnancy Test 3 x x x x x x 
 xs 
Plasma Antipsychotic Levels x x x 
PK and  xs xs xs  
Review of Adverse Events x x x x x x x x x x 
Concomitant Medications x x x x x x x x x x x 
Record Vital Signs/Weight9 x x x x x x x x 
NSA-16 x x x x x x 
PANSS x x x x x x 
MCCB10 x x x x 
CGI-S x x x 
COSS x x x x x x 
CGI-C x x 
PGIC x x 
RDoC Task (EEfRT) x x x 
Side Effects Scales x x x (AIMS, BAS , SAS) 
C-SSRS x x x x x x x x 
Dispense Study Medication x x x x 
Dose in Clinic x x x x x x x 
Review and/or Return Unused xs x x x xs x x x Study Medication .. I. V1s1ts 3 and 6 have a +3 day window . 
2. Visits 2, 4, 5, and 7 have a ±3 day window . 
3. Urinary (beta-hCG) test will be performed for all females regardless of childbearing potential (serum beta-hCG at Screening only) . Fasting 
glucose and lipids will be measured at Screening, Visit 4, and Visit 7/ET . 
4. Final visit or Early Termination Visit for patients who withdraw prior to study completion. 
5. PK blood draws will be taken 2-3 hours post-dose for Baseline , Visit 4, and Visit 7/ET.  
 
 
6. Electrocardiogram will be performed prior to dosing and 2-3 hours post-dosing for Visits 1 and 4. Post-dose only for Visit 7. Triplicate 
ECGs at Screening only. 
7. Telephone call will have a +3 day window . Post study exit calls will be daily for S days to assess any changes in health (AEs)/concomitant 
medications. 
8. Patient will be asked if they have taken their medications as directed during telephone calls on Days 8 and SO. 
9. Height will be measured at Screening only. 
10. The MCCB should be conducted at approximately the same time of day(+/ - 2 hours) and preferably in the AM. After the Screening Visit, 
patients who use sedatives/hypnotics or benzodiazepine medications on a pm basis should not take any of these medications the day of, or 
the day before , the assessment of cognitive function by MCCB . Patients who are on stable dose regimens of sedatives/hypnotics or 
benzodiazepine medications should take their medication as prescribed . 
Confidential Page 47 of52 

Statistical Analysis Plan: I 5-A VP-786-202 
 
Confidential Page 48 of52 

Statistical Analysis Plan: 15-A VP-786-202 
Confidential Page 49 of 52 

Statistical Analysis Plan: 15-A VP-786-20 
Appendix 3 Prior and Concomitant Medication Start Date Imputation 
Imputation Rules for Partial Dates (D =day, M =month, Y =year) 
Parameter Missing Additional Conditions Imputation 
Start date for Donly M and Y same as M and Y of first Date of first dose of study drug 
con meds dose of study drug 
Mand/or Y not same as date of first First day of month 
dose of study drug 
MandD Y same as Y of first dose of study drug Date of first dose of study drug 
Y not same as Y of first dose of study Use Jan 01 ofY 
drug 
M, D, and Y None -date completely missing Day prior to date of first dose 
of study drug 
Stop date for D only M and Y same as M and Y of last dose Date of last dose of study drug 
con meds of study drug 
M and/or Y not same as date of last Last day of month 
dose of study drug 
MandD Y same as Y of last dose of study drug Date of last dose of study drug 
Y not same as Y of last dose of study Use Dec 31 ofY 
drug 
M, D, and Y None -date completely missing and Date of last dose of study drug 
NOT ongoing 
Note: In all cases, ifan estimated start date is after a complete stop date, use the first day of the stop date 
month. 
Similarly, ifthe estimated stop date is before a complete or imputed start date, use the last day of the start 
day month. 
Confidential Page 50 of 52 

Statistical Analysis Plan: 15-A VP-786-202 
 
Confidential Page 51of52 

Statistical Analysis Plan: 15-A VP-786-202 
Appendix 5 List of Selective Serotonin-norepinepherine Reuptake Inhibitors (SNRis) 
Preferred Term Trade Names 
V enlafaxine Efexor, Effexor 
Sibutramine Meridia, Reductil 
Duloxetine Cymbalta, Ariclaim, Xeristar, Y entreve 
Atomoxetine Strattera 
Desvenlafaxine Pristiq 
Milnacipran Savella, Ixel, Dalcipran, Toledomin 
Levomilnaci pran Fetzima 
Confidential Page 52 of52 
